Navigation Links
Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
Date:2/23/2011

DEERFIELD, Ill. and OSAKA, Japan, February 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD) for the treatment of hypertension, or high blood pressure. Discovered by Takeda, azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Chlorthalidone is a long-acting oral thiazide-like diuretic used in the treatment of hypertension. The NDA submission was supported by four phase 3 clinical trials involving more than 4,000 patients with hypertension.

“Millions of patients with hypertension do not have their condition under control,” said Darryl Sleep, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc. U.S. “We believe this compound, the first in the U.S. to combine an ARB with chlorthalidone, could potentially provide an important new treatment option for patients with hypertension and the health care providers who manage them.”

In a phase 3 clinical trial, azilsartan medoxomil (20 mg/day, 40 mg/day and 80 mg/day), combined in a fixed-dose with CLD (12.5 mg/day and 25 mg/day), was studied versus azilsartan medoxomil and CLD monotherapies. In other studies, the fixed-dose combination of azilsartan medoxomil plus CLD was compared to azilsartan medoxomil coadministered with hydrochlorothiazide (HCTZ), another diuretic, and with a fixed-dose combination of olmesartan medoxomil and HCTZ.

Results from a phase 3 clinical trial of the fixed-dose combination of azilsartan medoxomil plus CLD were previously presented at the American Society of Hypertension, Inc. (ASH), 25th Annual Scientific Meeting and Expositio
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
3. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
4. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Takeda Responds to FDA Advisory Committee Recommendation
7. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
8. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
9. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... May 8, 2012 Stereotaxis, Inc. (NASDAQ:   ... to the European market the V-Sono™ intracardiac echocardiography ... Designed to manipulate accessory devices such ... catheters, the Vdrive™ platform combines magnetic navigation with ...
...  Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ), a ... of medically important pharmaceutical products for the treatment of ... the first quarter ended March 31, 2012. ... equivalents, interest receivable, and investment securities of $31.0 million, ...
Cached Medicine Technology:Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 2Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 4
(Date:8/29/2014)... As reported by CNN.com in the article Prescription ... admitting that you need help for a prescription drug abuse ... the fact that if you simply try to find general ... all of the information that is available online. Although the ... is still possible to get help. The statistics from SAMSHA ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... Mar, CA (PRWEB) August 29, 2014 A ... bra,” a bra developed by a Tokyo clothing store for ... in the hopes of rectifying or diminishing their problem. Board-certified ... treated men with the problem. While many people only associate ... actually a fairly common condition among men of all ages, ...
(Date:8/29/2014)... Chicago, IL (PRWEB) August 29, 2014 ... FindSurrogateMother.com is set to unveil a stunning new ... According to company figures, the highly notable surrogacy platform ... since January. With over 13,000 visitors a month, the ... surrogate mothers working toward one common goal — the ...
(Date:8/29/2014)... new report released yesterday by the Mental Health ... mental health training and education that police personnel ... prominent issue for Canada,s police community, and today,s ... law enforcement and people with mental illnesses," says ... with an interest in the area of police ...
Breaking Medicine News(10 mins):Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Report advocates improved police training 2
... 17 (HealthDay News) -- It,s normal and healthy for ... housing assistance, according to a new study. The ... involves slacker young adults who refuse to grow up ... children,s development, said the researchers. They analyzed data ...
... cartilage implants created using stem cells can only be ... measure before the almost inevitable need for total joint ... are investigating the possibilities of a biologically-engineered synthetic liquid ... by offering a one stop, permanent solution. ...
... Many Baby Boomers will experience a bone fracture as they ... to provide the necessary care required, according to a special ... Orthopaedic Surgery and Rehabilitation (GOS), published by SAGE. ... Baby Boom generation will reach 65 years old this year. ...
... WHAT: ... improve lung function and quality of life in individuals living with ... new study sponsored and conducted in part by the National Heart, ... "Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis," will ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay News) -- A ... the high doses that are typically used to treat acute ... study finds. Cytarabine is used in the treatment of ... stem cell transplantation. Cytarabine resembles a normal cell nutrient needed ...
... that while the number of visits to state parks across ... been significantly reduced. The reduction in funding during a time ... economic impact that state parks have on the nation,s economy. ... stress on America,s state-park systems," says Dr. Yu-Fai Leung, NC ...
Cached Medicine News:Health News:Young Adults May Need 'Safety Net' 2Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:US healthcare system can't keep up with number of baby boomers' bone fractures 2Health News:Sirolimus therapy alleviates symptoms of lung disease LAM 2Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Study shows attendance at state parks grows, even as funding decreases 2
Angled 45 degree shafts 8 mm from tip to bend with 5 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Stra...
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Angl...
Straight shafts with 4 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: